Skip to main content
. Author manuscript; available in PMC: 2015 Apr 1.
Published in final edited form as: Clin Cancer Res. 2014 Jan 31;20(7):1856–1864. doi: 10.1158/1078-0432.CCR-13-2109

Figure 2. DNA Methylation of CDO1, HOXA9, and TAC1 is Highly Sensitive for NSCLC in the Cancer Genome Atlas.

Figure 2

A single Infinium methylation probe with the best discriminative capacity between tumor and normal samples was selected for each of the 3 genes. A sample is considered methylated for a gene if its β-value was larger than three times the standard deviation of the mean of β-values of normal samples. Methylation of at least one gene-promoter among CDO1, HOXA9, and TAC1 by Infinium array identifies 98.9% of NSCLC cases in 636 cases in The Cancer Genome Atlas.